158 related articles for article (PubMed ID: 6152198)
21. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
22. Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy--clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders".
Oertel WH; Trenkwalder C; Gasser T; Schwarz J; Bucher SF; Eichhorn T; Pogarell O; Künig G; Arnold G; Bandmann O
J Neural Transm Suppl; 1995; 46():325-37. PubMed ID: 8821069
[TBL] [Abstract][Full Text] [Related]
23. Looking backward to move forward: early detection of neurodegenerative disorders.
DeKosky ST; Marek K
Science; 2003 Oct; 302(5646):830-4. PubMed ID: 14593169
[TBL] [Abstract][Full Text] [Related]
24. Neural degeneration and the transport of neurotransmitters.
Edwards RH
Ann Neurol; 1993 Nov; 34(5):638-45. PubMed ID: 7902065
[TBL] [Abstract][Full Text] [Related]
25. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
Jamwal S; Kumar P
Curr Neuropharmacol; 2019; 17(2):165-175. PubMed ID: 29512464
[TBL] [Abstract][Full Text] [Related]
26. Network biomarkers for the diagnosis and treatment of movement disorders.
Poston KL; Eidelberg D
Neurobiol Dis; 2009 Aug; 35(2):141-7. PubMed ID: 19013242
[TBL] [Abstract][Full Text] [Related]
27. Mitochondria and neurodegeneration.
Petrozzi L; Ricci G; Giglioli NJ; Siciliano G; Mancuso M
Biosci Rep; 2007 Jun; 27(1-3):87-104. PubMed ID: 17486441
[TBL] [Abstract][Full Text] [Related]
28. [Progresses in the study of unbalance of basal ganglia neurotransmitters in Parkinson's disease].
Sun ZL; Jia J; Yu F
Sheng Li Ke Xue Jin Zhan; 2011 Dec; 42(6):427-30. PubMed ID: 22363981
[No Abstract] [Full Text] [Related]
29. Biochemistry of the basal ganglia.
Fahn S
Adv Neurol; 1976; 14():59-89. PubMed ID: 7932
[No Abstract] [Full Text] [Related]
30. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease.
Hausdorff JM; Cudkowicz ME; Firtion R; Wei JY; Goldberger AL
Mov Disord; 1998 May; 13(3):428-37. PubMed ID: 9613733
[TBL] [Abstract][Full Text] [Related]
31. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
Strange PG
Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
[TBL] [Abstract][Full Text] [Related]
32. [Current data on the pathogenesis of neurodegenerative diseases and some muscular disorders: therapeutic prospectives].
Vécsei L; Pál E
Orv Hetil; 1993 Aug; 134(31):1683-7. PubMed ID: 8341549
[TBL] [Abstract][Full Text] [Related]
33. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
[TBL] [Abstract][Full Text] [Related]
34. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain.
Curtis MA; Faull RL; Glass M
J Chem Neuroanat; 2006 Apr; 31(3):210-5. PubMed ID: 16533591
[TBL] [Abstract][Full Text] [Related]
35. Oxidative stress and neurotoxicity.
Sayre LM; Perry G; Smith MA
Chem Res Toxicol; 2008 Jan; 21(1):172-88. PubMed ID: 18052107
[TBL] [Abstract][Full Text] [Related]
36. Anatomy and pathology of the basal ganglia.
McGeer PL; McGeer EG; Itagaki S; Mizukawa K
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):363-72. PubMed ID: 2890425
[TBL] [Abstract][Full Text] [Related]
37. Second messenger systems in brains of patients with Parkinson's or Huntington's disease.
Tanaka C; Nishino N; Hashimoto T; Kitamura N; Yoshihara C; Saito N
Adv Neurol; 1993; 60():175-80. PubMed ID: 8093576
[TBL] [Abstract][Full Text] [Related]
38. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Hornykiewicz O
Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
[TBL] [Abstract][Full Text] [Related]
39. Harnessing endogenous stem cells to treat neurodegenerative disorders of the basal ganglia.
Mohapel P; Brundin P
Parkinsonism Relat Disord; 2004 Jul; 10(5):259-64. PubMed ID: 15196503
[TBL] [Abstract][Full Text] [Related]
40. Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Olney JW; Zorumski CF; Stewart GR; Price MT; Wang GJ; Labruyere J
Exp Neurol; 1990 Jun; 108(3):269-72. PubMed ID: 1972067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
